壮症的医疗治疗:一个网络元分析
Chrysi Kaparounaki1, Mirela-Diana Ilie2,3, Dario De Alcubierre4
1Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
European journal of endocrinology
|October 27, 2025
概括
佩格维索曼特和沙雷胺LAR是最有效的正常化胰岛素样生长因子1 (IGF-1) 在壮病. 帕西里奥提德LAR也显示了最好的瘤缩,尽管需要更多的研究.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 巨症是一种罕见的疾病,由生长激素分泌的垂体腺瘤引起.
- 有限的临床试验证据存在于巨病的管理.
- 医疗治疗的目的是使IGF-1水平正常化并减少瘤大小.
研究的目的:
- 为了比较各种医疗治疗壮症的疗效.
- 评估生化 (IGF-1正常化) 和放射性 (瘤缩) 反应.
- 为优化壮症管理提供证据.
主要方法:
- 系统审查和网络元分析.
- 搜索了PubMed,Scopus和科学网络,直到2024年6月.
- 包括随机对照试验和非随机研究.
主要成果:
- 佩格维索曼特和沙雷胺LAR在IGF-1正常化方面最有效.
- 与体静止素受体连接体 (SRLs) 相比,帕西雷奥提德LAR表现出优异的瘤缩.
- 佩格维索曼特和沙雷胺LAR在IGF-1正常化方面表现优于与多巴胺激动剂结合的SRL.
结论:
- 帕西里欧提德LAR和佩格维索曼特是促进IGF-1正常化治疗的有希望的治疗方法.
- 帕西里欧提德LAR显示出瘤缩的潜力,但证据有限.
- 需要进一步的研究来评估它们在手术后作为一线治疗的作用,考虑到成本和安全性.
相关概念视频
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Open Angle Glaucoma: Treatment
958
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
958
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319


